Early Rash Development May Signal Superior Benefit With Lapatinib

Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.

Targeted therapeutic options and future perspectives for HER2-positive breast cancer

Lapatinib

Number of days from start of lapatinib to onset of rash*

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Lapatinib: Package Insert

PARP inhibitors: enhancing efficacy through rational combinations

PDF) Lapatinib and lapatinib plus trastuzumab therapy versus

Biomedicines, Free Full-Text

Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer - ScienceDirect

Forest plot of the adverse events for lapatinib and trastuzumab: (A)

Frontiers Cutaneous manifestations associated with immune checkpoint inhibitors

Forest plots showing heterogeneity by rash phenotype in the TþL

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs